Journal Home > Volume 20 , Issue 2
BACKGROUND

Acute kidney injury (AKI) after coronary angiography (CAG) and primary percutaneous coronary intervention (PPCI) is frequently observed, and often interpreted as contrast induced-AKI. This study aimed to investigate the incidence, predictors and outcomes of AKI in acute ST-segment elevation myocardial infarction (STEMI) patients undergoing emergent CAG/PPCI using the control group of STEMI patients who were not exposed to contrast agents within the first 72 h.

METHODS

We performed a retrospective analysis of 1670 STEMI patients. Of them, 673 patients underwent emergent CAG/PPCI, and 997 patients treated with thrombolysis or no reperfusion therapy who were not exposed to contrast material during the first 72 h. AKI was defined as an increase of serum creatinine ≥ 44.2 mmol/L or ≥ 25% from baseline within 72 h. Patents were then followed up for the occurrence of all-cause mortality for 40 months (interquartile range: 24–55 months).

RESULTS

After propensity score matching, 505 pairs of patients were matched. Overall, the incidence of AKI was 27.4%, and AKI rates were not significantly different in patients with and without emergent CAG/PPCI procedure (27.5% vs. 27.3%, P = 0.944). Multivariate logistic regression analysis identified that the independent predictors of AKI were female, elevated interleukin-6 level, decreased lymphocyte count, left ventricular ejection fraction < 50% and use of diuretics in patients with emergent CAG/PPCI. Patients with AKI than those without AKI experienced higher incidence of acute heart failure with Killip class III (9.4% vs. 3.3%, P = 0.005; 15.2% vs. 6.8%, P = 0.003, respectively) and mortality (5.8% vs. 1.4%, P = 0.014; 12.3% vs. 4.6%, P = 0.002, respectively) in patients with and without emergent CAG/PPCI. Multivariate Cox regression analysis confirmed that AKI was independently associated with long-term mortality rate at 40 months follow-up in patients with and without emergent CAG/PPCI (HR = 1.867, 95% CI: 1.086–3.210, P = 0.024; HR = 1.700, 95% CI: 1.219–2.370, P = 0.002, respectively).

CONCLUSIONS

Approximately 27.0% of STEMI patients experience AKI, which is strongly associated with an increased short- and long-term mortality regardless of emergent CAG/PPCI procedure. The development of AKI is mainly related to female gender, inflammation reaction, heart failure and use of diuretics in STEMI patients undergoing emergent CAG/PPCI.


menu
Abstract
Full text
Outline
About this article

Incidence, predictors and prognosis of acute kidney injury in acute ST-segment elevation myocardial infarction patients undergoing emergent coronary angiography/primary percutaneous coronary intervention

Show Author's information Jing TAN1Ying-Hua ZHANG1Jin SI1Ke-Ling XIAO2Qi HUA1( )Jing LI2( )
Department of Cardiology, Xuanwu Hospital, Capital Medical University, Beijing, China
Department of Geriatric Medicine, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing, China

Abstract

BACKGROUND

Acute kidney injury (AKI) after coronary angiography (CAG) and primary percutaneous coronary intervention (PPCI) is frequently observed, and often interpreted as contrast induced-AKI. This study aimed to investigate the incidence, predictors and outcomes of AKI in acute ST-segment elevation myocardial infarction (STEMI) patients undergoing emergent CAG/PPCI using the control group of STEMI patients who were not exposed to contrast agents within the first 72 h.

METHODS

We performed a retrospective analysis of 1670 STEMI patients. Of them, 673 patients underwent emergent CAG/PPCI, and 997 patients treated with thrombolysis or no reperfusion therapy who were not exposed to contrast material during the first 72 h. AKI was defined as an increase of serum creatinine ≥ 44.2 mmol/L or ≥ 25% from baseline within 72 h. Patents were then followed up for the occurrence of all-cause mortality for 40 months (interquartile range: 24–55 months).

RESULTS

After propensity score matching, 505 pairs of patients were matched. Overall, the incidence of AKI was 27.4%, and AKI rates were not significantly different in patients with and without emergent CAG/PPCI procedure (27.5% vs. 27.3%, P = 0.944). Multivariate logistic regression analysis identified that the independent predictors of AKI were female, elevated interleukin-6 level, decreased lymphocyte count, left ventricular ejection fraction < 50% and use of diuretics in patients with emergent CAG/PPCI. Patients with AKI than those without AKI experienced higher incidence of acute heart failure with Killip class III (9.4% vs. 3.3%, P = 0.005; 15.2% vs. 6.8%, P = 0.003, respectively) and mortality (5.8% vs. 1.4%, P = 0.014; 12.3% vs. 4.6%, P = 0.002, respectively) in patients with and without emergent CAG/PPCI. Multivariate Cox regression analysis confirmed that AKI was independently associated with long-term mortality rate at 40 months follow-up in patients with and without emergent CAG/PPCI (HR = 1.867, 95% CI: 1.086–3.210, P = 0.024; HR = 1.700, 95% CI: 1.219–2.370, P = 0.002, respectively).

CONCLUSIONS

Approximately 27.0% of STEMI patients experience AKI, which is strongly associated with an increased short- and long-term mortality regardless of emergent CAG/PPCI procedure. The development of AKI is mainly related to female gender, inflammation reaction, heart failure and use of diuretics in STEMI patients undergoing emergent CAG/PPCI.

References(33)

[1]

Tsai TT, Patel UD, Chang TI, et al. Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI registry. JACC Cardiovasc Interv 2014; 7: 1−9.

[2]

Nemoto N, Iwasaki M, Nakanishi M, et al. Impact of continuous deterioration of kidney function 6 to 8 months after percutaneous coronary intervention for acute coronary syndrome. Am J Cardiol 2014; 113: 1647−1651.

[3]

James MT, Samuel SM, Manning MA, et al. Contrast-induced acute kidney injury and risk of adverse clinical outcomes after coronary angiography: a systematic review and meta-analysis. Circ Cardiovasc Interv 2013; 6: 37−43.

[4]

Amin AP, McNeely C, Spertus JA, et al. Incremental cost of acute kidney injury after percutaneous coronary intervention in the United States. Am J Cardiol 2020; 125: 29−33.

[5]

El-Ahmadi A, Abassi MS, Andersson HB, et al. Acute kidney injury: a frequent and serious complication after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. PLoS One 2019; 14: e0226625.

[6]

Kumar D, Liaquat H, Sial JA, et al. Risk factors associated with contrast-induced nephropathy after primary percutaneous coronary intervention. Cureus 2020; 12: e9721.

[7]

Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004; 44: 1393−1399.

[8]

Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604−612.

[9]

Levey AS, Inker LA, Coresh J. GFR estimation: from physiology to public health. Am J Kidney Dis 2014; 63: 820−834.

[10]

Yuan Y, Qiu H, Hu XY, et al. Risk factors of contrast-induced acute kidney injury in patients undergoing emergency percutaneous coronary intervention. Chin Med J (Engl) 2017; 130: 45−50.

[11]

Khalfallah M, Allaithy A, Maria DA. Incidence, predictors and outcomes of contrast induced nephropathy in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention. Glob Heart 2021; 16: 57.

[12]

Senoo T, Motohiro M, Kamihata H, et al. Contrast-induced nephropathy in patients undergoing emergency percutaneous coronary intervention for acute coronary syndrome. Am J Cardiol 2010; 105: 624−628.

[13]

Koowattanatianchai S, Chantadansuwan T, Kaladee A, et al. Practical risk stratification score for prediction of contrast-induced nephropathy after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction. Cardiol Res 2019; 10: 350−357.

[14]

Caspi O, Habib M, Cohen Y, et al. Acute kidney injury after primary angioplasty: is contrast-induced nephropathy the culprit? J Am Heart Assoc 2017; 6: e005715.

[15]

Gohbara M, Hayakawa A, Akazawa Y, et al. Association between acidosis soon after reperfusion and contrast-induced nephropathy in patients with a first-time ST-segment elevation myocardial infarction. J Am Heart Assoc 2017; 6: e006380.

[16]

He H, Chen XR, Chen YQ, et al. Prevalence and predictors of contrast-induced nephropathy (CIN) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI): a meta-analysis. J Interv Cardiol 2019; 2019: 2750173.

[17]

Fanola CL, Morrow DA, Cannon CP, et al. Interleukin-6 and the risk of adverse outcomes in patients after an acute coronary syndrome: observations from the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) trial. J Am Heart Assoc 2017; 6: e005637.

[18]

Markousis-Mavrogenis G, Tromp J, Ouwerkerk W, et al. The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study. Eur J Heart Fail 2019; 21: 965−973.

[19]

Simmons EM, Himmelfarb J, Sezer MT, et al. Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int 2004; 65: 1357−1365.

[20]

Nechemia-Arbely Y, Barkan D, Pizov G, et al. IL-6/IL-6R axis plays a critical role in acute kidney injury. J Am Soc Nephrol 2008; 19: 1106−1115.

[21]

Dennen P, Altmann C, Kaufman J, et al. Urine interleukin-6 is an early biomarker of acute kidney injury in children undergoing cardiac surgery. Crit Care 2010; 14: R181.

[22]

Hudzik B, Szkodzinski J, Danikiewicz A, et al. Serum interleukin-6 concentration predicts contrast-induced nephropathy in patients undergoing percutaneous coronary intervention. Eur Cytokine Netw 2010; 21: 129−135.

[23]

Butt K, D’Souza J, Yuan C, et al. Correlation of the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) with contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary interventions. Cureus 2020; 12: e11879.

[24]

Patschan D, Patschan S, Buschmann I, et al. Loop diuretics in acute kidney injury prevention, therapy, and risk stratification. Kidney Blood Press Res 2019; 44: 457−464.

[25]

Yildirim E, Cabbar AT. Association between copeptin and contrast-induced nephropathy in patients with ST-elevation myocardial infarction. Rev Port Cardiol (Engl Ed) 2019; 38: 873−879.

[26]

Celik IE, Kurtul A, Duran M, et al. Elevated serum fibrinogen levels and risk of contrast-induced acute kidney injury in patients undergoing a percutaneous coronary intervention for the treatment of acute coronary syndrome. Coron Artery Dis 2016; 27: 13−18.

[27]

Neugarten J, Golestaneh L. Female sex reduces the risk of hospital-associated acute kidney injury: a meta-analysis. BMC Nephrol 2018; 19: 314.

[28]

Frydman S, Freund O, Banai A, et al. Relation of gender to the occurrence of AKI in STEMI patients. J Clin Med 2022; 11: 6565.

[29]

Neugarten J, Sandilya S, Singh B, et al. Sex and the risk of AKI following cardio-thoracic surgery: a meta-analysis. Clin J Am Soc Nephrol 2016; 11: 2113−2122.

[30]

Narula A, Mehran R, Weisz G, et al. Contrast-induced acute kidney injury after primary percutaneous coronary intervention: results from the HORIZONS-AMI substudy. Eur Heart J 2014; 35: 1533−1540.

[31]

Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105: 2259−2264.

[32]

Wi J, Ko YG, Kim JS, et al. Impact of contrast-induced acute kidney injury with transient or persistent renal dysfunction on long-term outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention. Heart 2011; 97: 1753−1757.

[33]

Turan B, Erkol A, Gül M, et al. Effect of contrast-induced nephropathy on the long-term outcome of patients with non-ST segment elevation myocardial infarction. Cardiorenal Med 2015; 5: 116−124.

Publication history
Copyright
Acknowledgements
Rights and permissions

Publication history

Published: 22 February 2023
Issue date: February 2023

Copyright

© 2023 JGC All rights reserved

Acknowledgements

ACKNOWLEDGMENTS

All authors had no conflicts of interest to disclose. The authors would like to express their sincere thanks to the staff at the Xuanwu Hospital, Capital Medical University, Beijing, China, for their kind cooperation when conducting this study.

Rights and permissions

Return